2 FTSE 250 pharma stocks I’d buy today and hold for another five years

Roland Head takes a look at two unusual pharma stocks with long-term growth potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares of US pharma group Indivior (LSE: INDV) fell by as much as 20% on Friday morning, after a judge ruled against the firm in a patent case. But the share price bounced back rapidly and was only 7% lower after the first hour of trading.

Today I want to explain why the market still seems confident in Indivior — and why I share this view.

A race against time

Indivior’s main product is Suboxone, a treatment for opioid addiction that’s used widely in the US. Although cheaper generic alternatives are available in tablet form, many doctors prefer to prescribe Suboxone Film, a version that’s placed on the patient’s tongue where it quickly dissolves.

So far there are no generic alternatives to Suboxone Film, meaning that profit margins are high. But last week Indivior lost a court case against would-be generic rival Alvogen. The court ruled that Alvogen’s generic version doesn’t infringe any of the three patents involved in the case.

The US Federal Drug Administration hasn’t approved Alvogen’s product yet, so it can’t go to market straight away. Indivior also plans to appeal and has launched two new patent infringement claims against the company.

However, the likelihood of a generic Film product coming to market seems to be rising. Indivior warned on Friday that if this happens, it could result in “a rapid and material loss of market share for Suboxone Film … within months”.

A big opportunity?

It’s clear that it needs some new products. It plans to launch a new schizophrenia treatment later this year, but one of the firm’s biggest hopes is a new once-monthly addiction treatment called Sublocade. This has only just been launched, but the company believes annual sales could reach $1bn.

Given that the group’s current revenue is $1.1bn, I’d argue that Sublocade looks like a potential replacement for Suboxone Film.

This situation isn’t without risk. But Indivior ended last year with net cash of $376m and has an impressive track record, in my view. I continue to rate this as a buy-and-hold opportunity.

A safer alternative

One company that sits on the other side of the fence to Indivior is generic pharmaceutical specialist Hikma Pharmaceuticals (LSE: HIK).

When I last wrote about it in August I suggested it as a potential turnaround buy. I’m pleased to say that the group’s recent 2017 results confirmed this view. The figures also provided some welcome support for Hikma’s share price, which has risen by 25% since the results were published on 14 March.

The firm now has a new chief executive who is overseeing the consolidation of several manufacturing facilities and distribution centres in order to cut costs. Hikma has also launched 44 new compounds globally, expanding its product portfolio.

The group’s underlying financial performance remains strong. Underlying free cash flow rose from $59m to $235m last year. This enabled the firm to reduce net debt from $697m to $546m, while still providing cover for the group’s dividend.

Hikma shares currently trade on a 2018 forecast P/E of 17 with a prospective yield of 2%. With earnings expected to rise by 15% in 2019, I believe the stock could be a good long-term dividend-growth buy at current levels.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Would Warren Buffett buy BP shares, as oil excitement grows?

Warren Buffett is a big investor in the oil business, and BP's performance has been attracting investor attention in results…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

Here’s how long-term loyalty to UK shares can lead to dazzling returns!

The most successful UK and US share investors buy shares to hold for the long term, as this report shows.

Read more »

Investing Articles

NatWest has just smashed brokers’ dividend forecasts!

After NatWest delivered a Valentine’s Day surprise to investors, our writer thinks the experts may have to raise their dividend…

Read more »

Investing Articles

The NatWest share price slips in early trading despite positive FY 2024 results. What’s the deal?

The NatWest share price is down slightly this morning after the bank released its final results for 2024. Our writer…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

My Legal & General shares have climbed just 7% — so how come I’m sitting on a 20% gain?

Harvey Jones' trading account is showing only a modest return on his Legal & General Shares, but on drilling down…

Read more »

Investing Articles

Prediction: the BP share price could rise in 2025 (or it might fall!)

Following this week’s release of the energy giant’s 2024 results, our writer reviews the prospects for the BP (LSE:BP.) share…

Read more »

many happy international football fans watching tv
Investing Articles

What’s gone wrong with the FTSE 100’s ‘King of Trainers’?

Feeling the pain of a 28% drop in the JD Sports share price over the past three months, our writer…

Read more »

Investing Articles

Is it too late for investors to consider buying these outstanding FTSE 100 shares?

Stephen Wright wonders whether now's the time to consider buying shares in the FTSE 100’s outstanding companies, despite some high…

Read more »